RxDoctor Payments Data

Priti Jadav, MD

Internal Medicine · Sugarland, TXNPI 1609806793

Payments from drug & device makers

$4,579in general payments, 2019–2025

Across 238 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$509
  • Amarin Pharma, Inc.$452
  • Amgen$382
  • Abbott$194
  • Kowa Pharmaceuticals America, Inc.$173
  • plus $524 from 13 others

What the payments were for

  • Food & beverage$4,47198%
  • Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,579 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$146,361
Medicare patients
210
Services billed
2,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab204$350,836
OzempicSemaglutide116$140,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$117,059
Breztri AerosphereBudesonide/Glycopyr/Formoterol81$110,743
FarxigaDapagliflozin Propanediol95$103,930
TrulicityDulaglutide73$101,966
JardianceEmpagliflozin44$56,082
MounjaroTirzepatide29$49,175
EliquisApixaban31$44,565
XareltoRivaroxaban33$35,617
SynjardyEmpagliflozin/Metformin Hcl19$32,611
RybelsusSemaglutide18$30,628
MyrbetriqMirabegron20$25,665
Synjardy XrEmpagliflozin/Metformin Hcl13$23,483
Rosuvastatin Calcium933$23,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$382$350,836204 claims
AstraZenecaBreztri Aerosphere, Farxiga$2,346$214,672176 claims
Novo NordiskOzempic, Rybelsus$37$170,681134 claims
Lilly USA, LLCTrulicity, Mounjaro$14$151,141102 claims
GSKTrelegy Ellipta$509$117,05980 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$14$112,17676 claims
PfizerEliquis$14$44,56531 claims
Johnson & JohnsonXarelto$134$35,61733 claims
Astellas Pharma US IncMyrbetriq$114$25,66520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sugarland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →